Comparison of Outcomes Following a Switch From a Brand to an Authorized Versus Independent Generic Drug

By  

CLINICAL PHARMACOLOGY & THERAPEUTICS, Vol. 103, Iss. 2, 2018-02 ,pp. : 310-317

John Wiley & Sons Inc

Access to resources Recommend Favorite

P149: Interim analysis for sofosbuvir national treatment program in Egypt

By  

JOURNAL OF VIRAL HEPATITIS (ELECTRONIC), Vol. 22, Iss. S2, 2015-06 ,pp. : 94-94

John Wiley & Sons Inc

Access to resources Recommend Favorite

Mechanistic versus allometric models for the prediction of drug clearance in neonates (<3 months of age)

By  

JOURNAL OF CLINICAL PHARMACOLOGY (ELECTRONIC), Vol. 55, Iss. 6, 2015-06 ,pp. : 718-720

John Wiley & Sons Inc

Access to resources Recommend Favorite

Rethinking Models of Psychotropic Drug Action

By  

Psychotherapy and Psychosomatics, Vol. 74, Iss. 3, 2005-04 ,pp. : 145-153

Karger

Access to resources Recommend Favorite

Greater first year effectiveness drives favorable cost-effectiveness of brand risedronate versus generic or brand alendronate: modeled Canadian analysis

By Grima D.   Papaioannou A.   Thompson M.   Pasquale M.   Adachi J.  

Osteoporosis International, Vol. 19, Iss. 5, 2008-05 ,pp. : 687-697

Springer Publishing Company

Access to resources Recommend Favorite